Krystal Biotech, Inc.

Valuation Analysis

About the Company

Krystal Biotech, Inc. en bref

Krystal Biotech, Inc. (KRYS) is currently trading at 303,43 € with a market capitalization of 8,9 Md €. The trailing P/E ratio stands at 46.53x, with a forward P/E of 34.53x. The 52-week range spans from 113,48 € to 310,78 €; the current price is 2.4% below the yearly high. Year-over-year revenue growth stands at +31.9%. The net profit margin stands at 53.92%.

💰 Dividende

Krystal Biotech, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Krystal Biotech, Inc. (KRYS) au consensus : Achat Fort. L'objectif de cours moyen est de 286,32 €, soit un potentiel de -5.64% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 210,10 € à 347,83 €.

Krystal Biotech, Inc. : la thèse d'investissement en détail

Krystal Biotech, Inc. (KRYS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 31.9% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 94.17%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 53.92%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Short interest sits at 17.53% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

The EV/EBITDA multiple of 48.31x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The forward P/E of 34.53x is meaningfully below the trailing 46.53x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 96.3% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (17.53%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Krystal Biotech, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.